Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial-Reference-Cited by-同舟云学术

Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial

Published:2021-02 Issue:2 Volume:27 Page:153-162
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Ganguly Siddhartha,Cortes Jorge E.,Krämer Alwin,Levis Mark J.,Martinelli Giovanni,Perl Alexander E.,Russell Nigel H.,Arunachalam Meena,Santos Cedric Dos,Gammon Guy,Lesegretain Arnaud,Mires Derek E.,Pham Hoang,Wang Yibin,Khaled Samer K.

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference45 articles.

1. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?;Levis;Hematology Am Soc Hematol Educ Program,2013

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines. Acute myeloid leukemia. v3.2020. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed June 16, 2020.

3. Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus;Montesinos;Ann Hematol,2019

4. Achievement of complete remission (CR) with measurable residual disease (MRD) negativity is highly prognostic in patients (pts) with relapsed or refractory (R/R) acute myeloid leukemia (AML) receiving first salvage chemotherapy;Short;Blood,2019

5. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse;Levis;Blood,2011

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia;International Journal of Molecular Sciences;2024-08-30

2. Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report;Anti-Cancer Drugs;2024-07-08

3. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease;British Journal of Haematology;2024-05-09

4. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors;Current Treatment Options in Oncology;2024-05-02

5. Post-transplant maintenance therapy: emerging concepts and future perspectives;Japanese Journal of Transplantation and Cellular Therapy;2024